Article
Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance
13 Oct 2014
Abstract excerpt
BACKGROUND: Taxanes such as paclitaxel and docetaxel are used successfully to treat breast cancer, usually in combination with other agents. They interfere with microtubules causing cell cycle arrest; however, the mechanisms underlying the clinical effects of taxanes are yet to be fully elucidated. METHODS: Isogenic paclitaxel resistant (PACR) MDA‒MB‒231, paclitaxel resistant ZR75‒1 and docetaxel resistant (DOCR)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
